期刊文献+

精氨酸酶1在食管癌患者外周血的表达及其临床意义 被引量:7

The expression of arginase 1 in peripheral blood of esophageal cancer patients and its clinical significance
下载PDF
导出
摘要 目的检测精氨酸酶1(arginase1,Arg1)在食管癌中的表达,分析其与髓源性抑制细胞(myeloid-derived suppressorcells,MDSCs)消长的关系,探讨癌症患者机体免疫抑制状态的可能机制。方法应用流式细胞术检测30例食管癌患者PBMC中的MDSCs比例;实时荧光定量PCR检测PBMC中Arg1、IL-6和TNF-αmRNA的表达水平;酶联免疫吸附试验(ELISA)检测血浆Arg1,IL-6和TNF-α含量。结果食管癌患者外周血PBMC中MDSCs比例及Arg1的mRNA水平均明显高于健康对照组(P<0.05),而IL-6和TNF-α的mRNA水平均低于健康对照组(P<0.05)。食管癌患者血浆Arg1含量高于健康对照组(P<0.05),而IL-6和TNF-a含量与健康对照组相比无明显差异(P>0.05)。此外,食管癌患者Arg1 mRNA水平和蛋白水平均与MDSC含量呈正相关(P<0.01)。结论 Arg1在食管癌患者外周血中的高表达与MDSCs水平和食管癌的发生、发展有着密切的关系,其检测将有助于临床食管癌的辅助诊断和预后判断。 This study aimed to investigate the levels of arginase 1(Arg1) in peripheral blood from esophageal cancer(ECA) patients,and analyze the relationship between Arg1 and myeloid-derived suppressor cells(MDSCs).The frequency of MDSCs in 30 cancer patients and 20 healthy blood donors was detected by flow cytometry.Quantitative real-time PCR(qRT-PCR) was used to determine the expression levels of Arg1,IL-6,and TNF-α mRNA in PBMC of all subjects.The concentration of Arg1 in plasma was also assessed by ELISA.The results showed that the expression levels of MDSCs and Arg1 mRNA in PBMC form ECA patients were higher compared with healthy controls(P 〈 0.05),while the levels of IL-6 and TNF-α mRNA were significantly lower.And the plasma level of Arg1 was obviously higher in ECA patients(P 〈 0.05),but there was no difference in the concentration of IL-6 and TNF-α between two experiment groups.In addition,there was a positive correlation between Arg1 and MDSC(P 〈 0.01).All the results suggested that the enhanced Arg1 may contribute to high level of MDSCs and ECA progression and growth.
出处 《免疫学杂志》 CAS CSCD 北大核心 2012年第11期972-975,980,共5页 Immunological Journal
基金 国家自然科学基金(30972748 31170849 31270947) 江苏大学大学生科研立项(11A383)
关键词 食管癌 精氨酸酶1 MDSCS 实时荧光定量PCR 酶联免疫吸附试验 Esophageal cancer Arginase 1 Myeloid-derived suppressor cells Real time fluorescentquantitative PCR ELISA
  • 相关文献

参考文献16

  • 1张银粉,周航.肿瘤的免疫逃逸机制研究进展[J].免疫学杂志,2011,27(4):346-349. 被引量:23
  • 2Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system[J]. Nat Rev Immunol, 2009, 9(3): 162-174.
  • 3谢伟,朱波.髓系衍生抑制性细胞与肿瘤免疫耐受[J].免疫学杂志,2010,26(9):816-818. 被引量:5
  • 4Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer[J]. J Immunol, 2001, 166(1): 678-689.
  • 5Filipazzi P, Valenti R, Huber V, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine[J]. J Clin Oncol, 2007, 25(18): 2546-2553.
  • 6Zea AH, Rodriguez PC, Atkins MB, et al. Arginase- producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion[J]. Cancer Res, 2005, 65(8): 3044-3048.
  • 7Ochoa AC, Zea AH, Hernandez C, ct al. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma[J]. Clin Cancer Res, 2007, 13(2Pt2): 721s-726s.
  • 8Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients[J]. Cancer Res, 2006, 66(18): 9299-9307.
  • 9Fricke I, Mirza N, Dupont J, et al. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses[J]. Clin Cancer Res, 2007, 13(16): 4840- 4848.
  • 10Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?[J]. Lancet, 2001, 357(9255): 539-545.

二级参考文献26

  • 1徐新保,冷希圣,杨晓,何振平.阻断TGF-β_1信号传导在减缓四氯化碳/乙醇诱导的小鼠肝细胞癌发展中的作用[J].中华医学杂志,2004,84(13):1122-1125. 被引量:11
  • 2李昭辉,王占民,赵志伦,张勇.Fas和FasL在胃癌组织中的表达[J].中国现代普通外科进展,2004,7(5):292-293. 被引量:6
  • 3向青,徐波,徐梅.Fas/FasL途径介导的人肺癌细胞免疫逃逸[J].中国病理生理杂志,2006,22(1):168-171. 被引量:15
  • 4孙正魁,姚榛祥.肿瘤相关巨噬细胞STAT3信号途径在抗乳腺癌免疫应答中的作用[J].免疫学杂志,2006,22(6):635-638. 被引量:2
  • 5Young MR, Newby M, Wepsic HT. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors [J]. Cancer Res, 1987, 47(1): 100-105.
  • 6Diaz Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy[J]. Cancer Immunol Immunother, 2009, 58 (1): 49-59.
  • 7Marigo I, Dolcetti L, Serafini P, et al. Tumor-induced tolerande and immune suppression by myeloid derived suppressor cells[J]. Immunol Rev, 2008, 222 (1): 162-179.
  • 8Gabrilovich DI, Bronte V, Chen SH, et al. The terminology issue for myeloid-derived suppressor cells [J]. Cancer Res, 2007, 67 (1): 425-426.
  • 9Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism [J]. Nat Rev Immunol, 2005, 5 (8): 641-654.
  • 10Pak AS, Wright MA, Matthews JP, et al. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34^+ cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor [J]. Clin Cancer Res, 1995, 1 (1):95-103.

共引文献26

同被引文献77

  • 1张琰,温浩,林仁勇,卢晓梅,张雪,冯晓辉,赵晋明,张静萍.细粒棘球蚴病患者淋巴细胞及细胞因子变化的初步观察[J].中国寄生虫学与寄生虫病杂志,2007,25(3):209-212. 被引量:12
  • 2Yoshida S, Kaibara A, Ishibashi N, et al. Glutamine supplementation in cancer patients[J]. Nutrition, 2001, 17(9): 766-768.
  • 3GramLich L, Kichian K, Pinilla J, et al. Dose enteral nutrition compared to parenteral nutrition result in better outcomes in critically ill adult patients: a systematic review of the literature[J]. Nutrition, 2004, 20(10): 843-844.
  • 4Peter JV, Moran JL, Jennie PH. A meta analysis of treatment outcomes of early entcral versus early parenteral nutrition in hospitalized patients[J]. Crit Care Med, 2005, 33(1): 213-220.
  • 5Radrizzani D, BenoliIli G, Facchini R, et al. Eady enteral immunonrnrition vs parenteral nutrition in critically ill patients without severe sepsis: a randomized clillical trial[J]. Intensive Care Med, 2006, 32(8): 1191-1198.
  • 6Purandare S, Offenbartl K, Siltharm S, et al. Increased gut permeability fluoreseein is othiocyanate dextran at~er total parenteraI nutrition in therat[J]. Stand J Gastroenteral, 1989, 24: 6782-6782.
  • 7Waitzberg DL, Torrinhas RS, Jacintho TM. New parenterallipid emulsions for clinical use [J]. Parenteral Enteral Nutr, 2006, 30(4): 351-367.
  • 8Ikutani M, Yanagibashi T, Ogasawara M, et al. Identification of innate IL-5-producing cells and their role in lung Eosinophil regulation and antitumor immunity[J]. J Immunol, 2012, 188(3): 703-713.
  • 9Neill DR, McKenzie AN. Nuocytes and beyond: new insights into helminth expulsion[J]. Trends Parasitol, 2011, 27(5): 214-221.
  • 10Wong SH, Walker JA, Jolin HE, et al. RORct is essential for nuoeyte development[J]. Nat Immunol, 2012, 13(3): 229-236.

引证文献7

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部